Similar articles

• High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.

  Reichard O, Foberg U, Frydén A, Mattsson L, Norkrans G, Sönnerborg A, Wejstål R, Yun ZB, Weiland O. Reichard O, et al. Hepatology. 1994 Feb;19(2):280-5. Hepatology. 1994. PMID: 7507462 Clinical Trial.
• Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.

  Rocha CM, Perez RM, Narciso JL, Ferreira AP, Lemos LB, Medina-Pestana JO, Silva AE, Ferraz ML. Rocha CM, et al. Eur J Gastroenterol Hepatol. 2007 Feb;19(2):119-23. doi: 10.1097/01.meg.0000252626.73172.f3. Eur J Gastroenterol Hepatol. 2007. PMID: 17272996 Clinical Trial.
• Treatment of acute hepatitis C with interferon alfa-2b.

  Tocci G, Visco-Comandini U, Antonucci G. Tocci G, et al. N Engl J Med. 2002 Apr 4;346(14):1091-2. N Engl J Med. 2002. PMID: 11936121 No abstract available.
• Hepatitis C virus infection in dialysis and renal transplantation.

  Pereira BJ, Levey AS. Pereira BJ, et al. Kidney Int. 1997 Apr;51(4):981-99. doi: 10.1038/ki.1997.139. Kidney Int. 1997. PMID: 9083262 Review. No abstract available.
• [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].

  Vega Palomares R, Planas Vilà R, Durández Lazaro R, Fábregas Puigtió S. Vega Palomares R, et al. Gastroenterol Hepatol. 2002 Oct;25(8):483-6. Gastroenterol Hepatol. 2002. PMID: 12361528 Review. Spanish.